恩度联合NO方案化疗治疗晚期非小细胞肺癌的临床观察

CLINICAL STUDY ON ENDOSTAR COMBINED WITH VINORELBINE AND OXALIPLATIN IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

目的观察长春瑞宾(vinorelbine,NVB)、奥沙利铂(oxaliplatin,OXA)联合恩度一线治疗晚期非小细胞肺癌的近期疗效及毒副反应。方法50例晚期非小细胞肺癌患者随机分为2组,治疗组(24例)给予NVB 25mg/m2第1、5 d,OXA 130 mg/m2,第1 d,恩度7.5 mg/m2,常用15 mg,连用14 d,休息1周。对照组(26例)仅给予常规NO方案化疗。21d为1周期,均至少完成2周期化疗,2周期后按WHO标准评价近期疗效、毒副反应。结果治疗组有效率为58.3%,对照组有效率30.8%,有显著性差异(P<0.05)。中位疾病进展时间分别为6.6月和3.7月(P<0.05)。两组毒副反应发生率无显著性差异,主要毒副反应为骨髓抑制、周围神经毒性及胃肠道反应。结论NO联合恩度方案治疗晚期非小细胞肺癌是合理、安全、有效的一种可行性方案,可以作为一线方案在临床推广。

Objective To determine the efficacy and toxicity of endostar in combination with vinorelbine（NVB） and oxaliplatin（OXA） as first-line treatment in advanced non-small cell lung cancer（NSCLC）. Methods Fifty cases with advanced NSCLC were enrolled into this study, 50 cases were randomly divided into endostar group （24 cases） and routine chemotherapy group （26 cases）. Endostar group（treatment group） was treated with endostar 7.5 mg/m^2·d^-1, intravenousdrip,l^14 d; NVB 25 mg/m^2·d^-1,intravenous drip,1 d,5 d;OXA 130 mg/m^2·d^-1 ,intravenous drip,d 1. Routine chemotherapy group （control group）was treated with NVB 25 mg/m^2·d^-1 , intravenous drip, 1d, 5d; OXA 130 mg/m^2·d^-1,intravenous drip, 1 d. Three weeks were regards as one cycle in two groups. All patients received two cycles of chemotherapy at least. The efficacy and toxicity were ＇evaluated according to WHO standard. Results The overall response rate was 58.3% in treatment group versus 30.8% in control group, with significant difference between the two groups in statistical analysis （ P〈0.05）. Median time to progression （mTTP） was 6.6 months in treatment group and 3.7 months in control group（P〈0.05）. The main toxicities were leucopenia, nausea/vomiting and peripheral neuritis. The total incidence of side effects in treatment group were simillar to those in control group （P〉0.05）.Conclusion Endostar combined with NVB and OXA were efficient and safe in the treatment of advanced NSCLC. It may be worthy of further clinical investigation.